Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Corporate Update (August 2021)
18 slides from Oncotelic Therapeutics's corporate update, Aug 26, 2021
Slide 1: Oncotelic / Mateon Therapeutics: A TGF-beta Company
ONC@OTELIC MATEON THERAPEUTICS A TGF-beta Company 8/24/2021 WWW.ONCOTELIC.COM
Slide 2: Forward-looking Statements
Forward-looking Statements * This document contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in t
Slide 3: PointR.ai, Oncotelic, Mateon Therapeutics
PointR.ai ONCOTELIC™ MATEON THERAPEUTICS Edge Computing Antisense Platform TGF-B Vision Grid -Target to FIH < lyr -A critical target in -Back office support -Exceptional Stability (>30 yrs) Oncology and COVID-19 vpwansoroa yeurossne -Blockchain/Smart Protocol FA Baseline R @ In | Wy Cluster- Antisen
Slide 4: OT-101 and Artemisinin / COVID
ONCOTELIC MATEON THERAPEUTICS OT-101. and Artemisinin/ COVID WWW.ONCOTELIC.COM
Slide 5: Conventional COVID-19 Therapeutics
ntional COVID-19 Therapeutics Lopinavir Hydroxychloroquine Remdesivir Interferon Kevzara® (sarilumab) Actemra (tocilizumab) laris® (canakinumab) Jakavi® (ruxolitinib) Bamlanivimab/ LY-CoV555 Convalescent plasma Azithromycin Ivermectin Artemisinin/ ARTIVeda/PulmoHeal Dexamethasone ONCOTELIC THERAPEUT
Slide 6: TGF-beta is the right target for COVID-19
TGF-beta is the right target for COVID-19 « Large surge in TGF-beta during active COVID infection « An established role of TGF-beta in scarring and late stage post-COVID symptoms ost intensve core syndrome / _Post-pulmonery emboism syndrome MODS | bviyed pharmacolegelovcty Paycologcl effets ‘LA, IL-
Slide 7: TGF-B Positive Feedback Loop
TGF-B Positive Feedback Loop > SAR-CoV-2 infection upregulates TGF-B and Furin. | Stukalov A et al. bioRxiv.2020.06.17.156455 Furin- SARS-CoV-2- > TGF-B locks cell cycle allowing the virus to replicate. Cellular ‘eluted slags x . . . Entry of TGF-B and >» TGF-B drives the expression of Furin- a prot
Slide 8: Impacts of TGF-B Surge
Impacts of TGF-B Surge ¢ Inflammation Thrombosis Inflammation * Systemic Inflammation / «Vascular Vasculitis olgA Pneumonia | «Wet Cough Fibrosis ) © Scarring ONCOTELIC THERAPEUTICS TGF-B recruits neutrophils into the site of inflammation laying down neutrophil extracellular traps (NET’s) responsibl
Slide 9: COVID-19 Clinical Course After SARS-CoV-2 Infection and the OT-101 Trial
COVID-19 CLINICAL COURSE AFTER SARS-COV-2 INFECTION AND THE OT-101 TRIAL Eligible Hospitalized Patients Eligible Hospitalized Patients Positive D-19: Positive for COVID-19: (WHO Ordinal Scale 3 and 4) + Severe Disease (WHO Ordinal Scale 5 and 6) a Post intensive core syndrome Innate immune response
Slide 10: COVID variants: Lambda and Delta
* Peru /Argentina= Lambda * India = Delta ce Arctic Gr Canada Vorth 7\ acific \cean Cuba = 4 o ra ® ¢ Bio Pard@uay South Pacitic ©... Ocean Se COVID variants HB 20H (seta, v2) eenland BB 201 (alpha, v2) 19A 20J (Gamma, V3) | 196 BB 21a welts) [0 20 [Bh 218 (kappa) 9 20c Iceland Sweden @ [BB 21c (Eps
Slide 11: Artemisinin - A naturally occurring TGF-B Inhibitor
Artemisinin - A naturally occurring TGF-B Inhibitor > Broad Activity/ Low Specificity > Narrow Activity/ High Specificity > Appropriate for rapid response to pandemic > Appropriate for safe and effective drugs Artemisinin Dihydroartemisinin Artemether Arteether sms0s m6 g SOs Bu me a H — Artemiside
Slide 12: TGF-B Inhibition by Artemisinin - Active Component of PulmoHeal
TGF-& Inhibition by Artemisinin- Active Component of PulmoHeal™ * Cao Y, Feng YH, Gao LW, et al. Artemisinin enhances the anti-tumor immune response in 471 breast cancer cells in vitro and in vivo. Int Immunopharmacol. 2019;70:110-116. « Zhang H, Qi S, Song Y, Ling C. Artemisinin attenuates early re
Slide 13: India Heart Care Foundation Protocol
India Heart Care Foundation Protocol * According to Dr K K Aggarwal (Heart care foundation) * COVID treatment * Code 1 - CONTACT : Ivermectin 12 ms and doxycycline 100 mg daily x 3 days, Betadine or neem gargles, Vitamins and minerals, Colchine 0.5 mg one daily for 21 days if CRP > 1. High protein d
Slide 14: India ARTI-19 Protocol
India ARTI-19 Protocol * Patients with mild/ moderate COVID without oxygen support * Compatible with: Seven Star Hospital COVID protocol: Remdesivir/Sompraz D/Zifi CV/Zac D/CCM/Broclear/Budamate/Rapitus/Montek LC/ lower molecular weight heparin/prednisolone/Doxycylline * Compatible with Raje Hospita
Slide 15: Outcomes (Primary/Secondary) of the Study - top line data of 120 pts
Outcomes (Primary/ Secondary) of the Study - top line data of 120 pts > 500 mg daily for 5 days use cough app to monitor clinical and cough severity. Consult with physician if symptoms persist or if tested positive for COVID. Treatment under physician care = 5 day on/5 day off for evaluation. Contin
Slide 16: Iran Imam Reza Hospital Protocol
Iran Iman Reza Hospital Protocol + Imam Reza Hospital, Sirjan Faculty of Medical Sciences, Iran with the reference number: IR.SIRUMS.REC.1399.033; IRCT registration number: IRCT20181030041504N1 + Intervention: Artemisinin, Hesperidin, Resveratrol, Noscapine, N-Acetyl Cysteine, and Vitamin C. Before
Slide 17: Recommended Treatment Schema
Recommend Treatment Schema ARTI-19 Protocol/ Pts not requiring 02/ PulmoHeal along with Standard COVID protocol per physician recommendation Suspected COVID/ Respiratory Symptoms . PulmoHeal — Once Daily for 5 days with cough app monitoring. Up to 3 cycles of 5 on/Soff Tested Positive for COVID or N
Slide 18: There is a massive fire of COVID out there
¢ There is a massive fire of COVID out there. « Limited resources on putting out the big fires will result in failure ¢ Need to target the fire that we currently have resources to put out. ¢ Use the cough apps to scope out the severity of the fire and identify controllable hot spots ¢ Deploy pulmohe
Oncotelic Therapeutics — Corporate Update (August 2021) on 6ix